Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Neuroscience Right
  3. Kisunla (donanemab-azbt) injection, for intravenous infusion Right
  4. What were the adverse reactions reported in Kisunla™ (donanemab-azbt) clinical trials?​
Search Kisunla™ (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Kisunla ™ (donanemab-azbt) injection, for intravenous infusion

350 mg/20 mL (17.5 mg/mL)

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What were the adverse reactions reported in Kisunla™ (donanemab-azbt) clinical trials?​

The most common adverse reactions in donanemab-treated participants in TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6 were amyloid-related imaging abnormalities, headache, and infusion-related reactions. Most events were mild or moderate in severity.

US_cFAQ_DON513A_TEAES_ESAD_OFF
US_cFAQ_DON513A_TEAES_ESAD_OFFen-US

See important safety information, including boxed warning, in the attached prescribing information.

TRAILBLAZER-ALZ 2 Trial

A phase 3, placebo-controlled 72-week study evaluated the safety and efficacy of donanemab in adults aged 60 to 85 years with early symptomatic Alzheimer's disease (AD).1

Participants were randomized at the beginning of double-blind treatment in a 1:1 ratio to receive intravenous infusions every 4 weeks of either

  • donanemab 700 mg for the first 3 doses and 1400 mg thereafter (n=860), or
  • placebo (n=876; administered as saline).1,2

Baseline demographics were similar between donanemab and placebo treatment groups. The 853 donanemab-treated participants were mostly female (57%) and white (91%), with a mean age of 73 years at study entry (range 59 to 86 years).1,3

In TRAILBLAZER-ALZ 2,

  • the frequency of treatment-emergent adverse events (TEAEs) was similar between the placebo (82.2%) and donanemab (89.0%) groups, and
  • most TEAEs were mild (placebo, 36.8%; donanemab, 35.9%) or moderate (placebo, 36.4%; donanemab, 41.1%) in severity.1,4 

Adverse reactions of donanemab were determined from the TEAE preferred terms reported in the study. Events were determined to be adverse reactions based on the strength of the association with donanemab treatment assessed using

  • predefined statistical criteria
  • biological plausibility for a donanemab effect
  • clinical importance, and
  • medical judgment.4

Adverse Reactions of Donanemab

The most frequently reported adverse reactions by donanemab-treated participants in TRAILBLAZER-ALZ 2 were

  • amyloid-related imaging abnormalities (ARIA)
  • headache, and
  • infusion-related reactions (Adverse Reactions Reported by ≥5% of Donanemab-Treated Participants and ≥2% Higher Than Placebo in TRAILBLAZER-ALZ 2).3
Adverse Reactions Reported by ≥5% of Donanemab-Treated Participants and ≥2% Higher Than Placebo in TRAILBLAZER-ALZ 23

Adverse Reactiona,b

Placebo
N=874
%

Donanemab
N=853
%

ARIA-H microhemorrhagec

11

25

ARIA-Ed

2

24

ARIA-H superficial siderosisc

3

15

Headache

10

13

Infusion-related reaction

0.5

9

Abbreviations: ARIA-E = amyloid-related imaging abnormalities-edema observed on MRI as vasogenic cerebral edema or sulcal effusions; ARIA-H = amyloid-related imaging abnormalities-hemosiderin deposition which includes superficial siderosis and microhemorrhage; MedDRA = Medical Dictionary for Regulatory Activities; MRI = magnetic resonance imaging; TEAE = treatment-emergent adverse event.

aMedDRA version 25.1.

bThis analysis set includes participant data from the first dose of treatment to the last dose plus 57 days.

cAs assessed by MRI. A participant could have both microhemorrhage and superficial siderosis.

dAs assessed by MRI or TEAE cluster.

The Appendix provides additional information on ARIA, including a description of the events and symptoms.

More information about the characterization of ARIA and infusion-related reactions in donanemab clinical trials is available here: ARIA, infusion-related reactions. 

Serious Adverse Events

A serious adverse event (SAE) is defined as any event or reaction that

  • results in death
  • is life-threatening
  • requires in-patient hospitalization or prolongation of existing hospitalization
  • results in persistent or significant incapacity or disability
  • is a congenital anomaly or birth defect, or
  • is a medically important event or reaction "for other reasons serious."4

The frequency of SAEs was similar between treatment groups in TRAILBLAZER-ALZ 2.1 Serious Adverse Events Occurring in ≥1% of Donanemab-Treated Participants: TRAILBLAZER-ALZ 2 shows SAEs that occurred in ≥1% of donanemab-treated participants while on treatment.

Serious Adverse Events Occurring in ≥1% of Donanemab-Treated Participants: TRAILBLAZER-ALZ 21,4

Preferred Term

Placebo
(N=874)
n (%)

Donanemab
(N=853)
n (%)

Deathsa

10 (1.1)

16 (1.9)

Participants ≥1 SAE

138 (15.8)

148 (17.4)

Syncope

13 (1.5)

9 (1.1)

ARIA-E

0 (0.0)

13 (1.5)

COVID-19

4 (0.5)

9 (1.1)

Abbreviations: ARIA-E: amyloid-related imaging abnormalities-edema observed on MRI as vasogenic cerebral edema or sulcal effusions; COVID-19 = coronavirus disease 19; MRI = magnetic resonance imaging; SAE = serious adverse event.

aDeaths are also included as SAEs.

Deaths

In the TRAILBLAZER-ALZ 2 study, deaths were reported in participants receiving

  • placebo (n=10, 1.1%), and
  • donanemab (n=16, 1.9%).1

A total of 3 participants in the donanemab treatment group reported serious ARIA and subsequently died. These deaths were attributed to

  • amyloid-related imaging abnormalities-edema (ARIA-E, n=1)
  • amyloid-related imaging abnormalities-hemosiderin deposition (ARIA-H, n=1), and
  • concurrent ARIA-E and ARIA-H (n=1).1

Discontinuations Due to Adverse Events

Discontinuations from study treatment due to adverse events were higher in the donanemab treatment group compared with the placebo group: Adverse Events Leading to Treatment Discontinuation in ≥0.5% of Donanemab Participants: TRAILBLAZER-ALZ 2.1,3

The most common adverse event leading to discontinuation of donanemab was infusion-related reaction (4%) compared to none on placebo.3

Adverse Events Leading to Treatment Discontinuation in ≥0.5% of Donanemab Participants: TRAILBLAZER-ALZ 21

Preferred Term

Placebo
(N=874)
n (%)

Donanemab
(N=853)
n (%)

Participants with treatment discontinuation due to AEs

38 (4.3)

112 (13.1)

Infusion-related reaction

0 (0.0)

31 (3.6)

ARIA-E

3 (0.3)

21 (2.5)

ARIA-H

2 (0.2)

7 (0.8)

Hypersensitivity

0 (0.0)

4 (0.5)

Abbreviations: AE = adverse event; ARIA-E = amyloid-related imaging abnormalities-edema observed on MRI as vasogenic cerebral edema or sulcal effusions; ARIA-H = amyloid-related imaging abnormalities-hemosiderin deposition; MRI = magnetic resonance imaging.

TRAILBLAZER-ALZ 2 Long-Term Extension

Participants who completed the placebo-controlled period of the TRAILBLAZER-ALZ 2 study were eligible to enter a 78-week double-blind long-term extension. Early start participants were those initially randomized to donanemab in the placebo-controlled period. Delayed start participants were those initially randomized to placebo in the placebo-controlled period and started donanemab in the long-term extension. Participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were selected as external control.5

No new safety signals were observed in the long-term extension study versus the established safety profile.5

TRAILBLAZER-ALZ 6 Trial

The TRAILBLAZER-ALZ 6 study investigated the impact of different donanemab dosing options on the frequency of ARIA-E in relation to amyloid reduction. All participants received a dosing regimen that includes donanemab, but at different dose levels and frequency of dosing. The modified titration regimen met the primary objective of >80% probability of achieving ≥20% reduction in relative risk of developing ARIA-E compared with the dosing regimen used in the TRAILBLAZER-ALZ 2 study (referred to as standard dosing in the TRAILBLAZER-ALZ 6 study).6 Therefore, the modified titration regimen is the recommended dosage for donanemab.3

In the modified titration regimen, participants received intravenous donanemab doses every 4 weeks as follows:

  • 350 mg for infusion 1
  • 700 mg for infusion 2
  • 1050 mg for infusion 3, and 
  • 1400 mg for infusion 4 and beyond.6

Safety Overview

At 76 weeks, the frequency of SAEs was 24.6% in the standard dosing and 23.1% in the modified titration arm. The rates of TEAEs were similar between the standard and modified titration arms (Safety Overview Through Week 76 in TRAILBLAZER-ALZ 6).6

Safety Overview Through Week 76 in TRAILBLAZER-ALZ 66,7

Categorya

Standard
(N=207)
n (%)

Modified Titration
(N=212)
n (%)

Deathsbc

 1 (0.5)

1 (0.5)d

SAEs

51 (24.6)

49 (23.1)

Discontinuations from study due to AEs

6 (2.9)

6 (2.8)

Discontinuations from treatment due to AEs

16 (7.7)

17 (8.0)

TEAEs

191 (92.3)

199 (93.9)

TEAEs related to study treatmente

110 (53.1)

114 (53.8)

Abbreviations: AE = adverse event; SAE = serious adverse event; TEAE = treatment-related adverse event.

aParticipants may be counted in more than one category

bDeaths are also included as SAEs and discontinuations due to AEs.

cPreferred term for cause of death: cardio-respiratory arrest (standard arm); cerebral haemorrhage (modified titration arm)

dDeath due to cerebral hemorrhage following thrombolytic administration for presumed acute right middle cerebral artery stroke.

eIncludes events that were considered related to study treatment as judged by the investigator.

Compared with rates reported in the standard arm, participants in the modified titration arm in TRAILABLAZER-ALZ 6 reported

  • higher rates of hypersensitivity reactions and infusion-related reactions and
  • a lower rate of ARIA-E.3

Treatment-emergent adverse reactions reported in more than 15% of participants in the modified titration arm (vs the standard arm) in TRAILBLAZER-ALZ 6 were

  • headache (20.3% vs 24.2%)
  • fall (19.8% vs 14.0%)
  • ARIA-H (18.4% vs 19.8%)
  • COVID-19 (17.9% vs 12.6%)
  • infusion-related reaction (17.9% vs 14.0%), and
  • ARIA-E (15.6% vs 24.2%).6

Discontinuation from study treatment due to adverse events occurred in

  • 16 (7.7%) participants in the standard arm, and
  • 17 (8.0%) participants in the modified titration arm.6 

Infusion-related reaction resulted in treatment discontinuation in 2.8% of donanemab-treated participants.3

Enclosed Prescribing Information

KISUNLA™ (donanemab-azbt) injection, for intravenous use, Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Sims JR, Zimmer JA, Evans CD, et al; TRAILBLAZER-ALZ 2 Investigators. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-527. https://doi.org/10.1001/jama.2023.13239

2Solomon PR. TRAILBLAZER-ALZ 2: clinical background and study design. Abstract presented at: Alzheimer's Association International Conference (AAIC); July 16-20, 2023; Amsterdam, Netherlands.

3Kisunla [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.

4Data on file, Eli Lilly and Company and/or one of its subsidiaries.

5Sims JR. Donanemab in early symptomatic Alzheimer’s disease: efficacy and safety from the TRAILBLAZER‐ALZ 2 long-term extension. Presented as an oral presentation at: Alzheimer's Association International Conference (AAIC); July 27-31, 2025; Toronto, Canada.

6Wang H, Nery ESM, Ardayfio P, et al. The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6. J Prev Alzheimers Dis. Published online July 5, 2025. https://doi.org/10.1016/j.tjpad.2025.100266

7Wang H, Nery ESM, Ardayfio P, et al. Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. Alzheimers Dement. 2025;21(4):e70062. https://doi.org/10.1002/alz.70062

8Sperling RA, Jack Jr CR, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367-385. https://doi.org/10.1016/j.jalz.2011.05.2351

9Cogswell PM, Barakos JA, Barkhof F, et al. Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice. AJNR Am J Neuroradiol. 2022;43(9):E19-E35. https://doi.org/10.3174/ajnr.A7586

10Ketter N, Brashear HR, Bogert J, et al. Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer’s disease patients. J Alzheimers Dis. 2017;57(2):557-573. https://doi.org/10.3233/JAD-160216

Appendix

Amyloid-Related Imaging Abnormalities Overview

Amyloid-related imaging abnormalities can be detected by brain magnetic resonance imaging (MRI) and have been observed in clinical trials of monoclonal antibodies directed against aggregated forms of beta amyloid.3,8 The 2 forms of ARIA are

  • ARIA-E, observed on MRI as vasogenic cerebral edema or sulcal effusions, and
  • ARIA-H, which includes microhemorrhage and superficial siderosis.3,8,9 

These are typically detected on different MRI sequences and are thought to share common underlying pathological mechanisms.8,9

Amyloid-related imaging abnormalities are usually asymptomatic although serious and life-threatening events, including seizure and status epilepticus, can occur. ARIA can be fatal. When present, reported symptoms associated with ARIA may include, but are not limited to, headache, confusion, visual changes, dizziness, nausea, and gait difficulty. Focal neurologic deficits may also occur. Symptoms associated with ARIA usually resolve over time.3

Also known as vasogenic edema, the mechanism of ARIA-E is thought to be a function of increased permeability of brain capillary endothelial cells to serum proteins resulting in increased extracellular fluid volume. It is generally

  • asymptomatic 
  • transient
  • reversible, and
  • not associated with cytotoxic edema, which results from cellular damage.8,9

In ARIA-H, hemosiderin deposits are present on MRI, including

  • microhemorrhages, leakage of blood from a vessel into the parenchyma 
  • superficial siderosis, leakage of blood from a vessel into adjacent the subarachnoid space or peri adventitial compartment, and
  • macrohemorrhages (intracerebral hemorrhage >1 cm in diameter).8,9

Microhemorrhages and superficial siderosis (ie, ARIA-H) are often associated with ARIA-E3 and both are thought to be possibly related to removal of vascular amyloid beta or amyloid trafficking at the blood-brain barrier.9,10

Date of Last Review: July 15, 2025

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.44 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly